Skip to Main Content
Table 1.
Clinical characteristics of CML patients
Characteristics (n = 93)Median (range)
Age (yr) 60.1 (23–85) 
Male/female 58/35 
Sokal risk (low/int./high) 59/24/4 
EUTOS risk (low/high) 73/5 
Prior IFN-α (+/−) 19/74 
CML duration (mo) 84.8 (13.2–229.4) 
Duration of IM treatment (mo) 75.7 (12.6–122.4) 
Actual daily IM dose (mg/d) 400 (66.7–400) 
Median time to CCyR (mo) 
From diagnosis to CCyR 6.6 (1–103.3) 
From IM therapy to CCyR 5.3 (0.5–76.7) 
Median time to MMR (mo) 
From diagnosis to MMR 19.5 (4.4–185.6) 
From IM therapy to MMR 17.0 (3.2–93.9) 
Characteristics (n = 93)Median (range)
Age (yr) 60.1 (23–85) 
Male/female 58/35 
Sokal risk (low/int./high) 59/24/4 
EUTOS risk (low/high) 73/5 
Prior IFN-α (+/−) 19/74 
CML duration (mo) 84.8 (13.2–229.4) 
Duration of IM treatment (mo) 75.7 (12.6–122.4) 
Actual daily IM dose (mg/d) 400 (66.7–400) 
Median time to CCyR (mo) 
From diagnosis to CCyR 6.6 (1–103.3) 
From IM therapy to CCyR 5.3 (0.5–76.7) 
Median time to MMR (mo) 
From diagnosis to MMR 19.5 (4.4–185.6) 
From IM therapy to MMR 17.0 (3.2–93.9) 

CCyR, complete cytogenetic response; EUTOS, European Treatment and Outcome Study; IM, imatinib; int., intermediate; MMR, major molecular response.

Close Modal

or Create an Account

Close Modal
Close Modal